Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $192 | $174 | $171 | $187 |
| % Growth | 10% | 2.3% | -8.6% | – |
| Cost of Goods Sold | $93 | $88 | $85 | $100 |
| Gross Profit | $99 | $86 | $85 | $87 |
| % Margin | 51.4% | 49.6% | 50% | 46.5% |
| R&D Expenses | $22 | $20 | $20 | $18 |
| G&A Expenses | $39 | $14 | $16 | $13 |
| SG&A Expenses | $51 | $24 | $28 | $23 |
| Sales & Mktg Exp. | $12 | $10 | $12 | $10 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $73 | $44 | $48 | $42 |
| Operating Income | $25 | $42 | $37 | $45 |
| % Margin | 13.2% | 24.2% | 21.9% | 24.2% |
| Other Income/Exp. Net | -$4 | -$3 | -$6 | -$1 |
| Pre-Tax Income | $22 | $39 | $31 | $44 |
| Tax Expense | $4 | $8 | $6 | $6 |
| Net Income | $17 | $31 | $25 | $38 |
| % Margin | 9% | 17.8% | 14.8% | 20.4% |
| EPS | 0.38 | 0.66 | 0.53 | 0.78 |
| % Growth | -42.4% | 24.5% | -32.1% | – |
| EPS Diluted | 0.37 | 0.64 | 0.51 | 0.74 |
| Weighted Avg Shares Out | 46 | 47 | 48 | 48 |
| Weighted Avg Shares Out Dil | 48 | 48 | 50 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $2 |
| Interest Expense | $6 | $6 | $6 | $6 |
| Depreciation & Amortization | $14 | $16 | $15 | $15 |
| EBITDA | $42 | $62 | $52 | $65 |
| % Margin | 21.9% | 35.5% | 30.7% | 34.9% |